Urinary bladder cancer following cyclophosphamide therapy for Hodgkin's disease.
Urinary bladder cancers following prolonged cyclophosphamide therapy are being increasingly reported. We report a case of transitional cell carcinoma of the urinary bladder occurring 12 years after pulse intravenous therapy with cyclophosphamide for Hodgkin's disease. The mechanism of bladder carcinogenesis and the possible role of the uroprotector MESNA in preventing cyclophosphamide induced bladder cancer are discussed.
Pathak
A B
AB
Department of Medical Oncology, Tata Memorial Hospital, Parel, Bombay, India.
Advani
S H
SH
Gopal
R
R
Nadkarni
K S
KS
Saikia
T K
TK
D003520:Cyclophosphamide / Q000009:adverse effects*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D015080:Mesna / Q000494:pharmacology; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced*
D003520:Cyclophosphamide; D015080:Mesna